(CLVT) Clarivate Plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CLVT) Clarivate Plc Complete Analysis Pack
Download Your Competitive Advantage
This Clarivate Plc BCG Matrix helps you see how the company’s businesses or offerings may fall across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
Web of Science Core Collection
Web of Science Core Collection is Clarivate Plc’s flagship citation index and the core of its academic research stack. In 2025, its sticky installed base supported strong renewals, since universities and labs use it for discovery, evaluation, and institutional reporting. That makes it the clearest Star in the portfolio, with deep switching costs and recurring demand.
Ex Libris Alma
Ex Libris Alma is Clarivate Plc’s cloud library services platform for academic and research libraries, and it fits the Star profile because it replaces legacy on-premise systems with SaaS workflows. That shift supports recurring revenue and strong platform economics, since libraries tend to stay once data, workflows, and integrations are embedded. Clarivate reported about $2.6 billion in 2024 revenue, underscoring the scale behind this subscription-led business.
Ex Libris Primo
Ex Libris Primo is a Star in Clarivate Plc’s BCG matrix because it is a core discovery layer that lets libraries search collections and content in one place. It rides the same cloud shift as Alma, and Clarivate’s recurring subscription model supports long contract renewals; in FY2024, Clarivate reported about $2.5 billion in revenue.
ScholarOne Manuscripts
ScholarOne Manuscripts is the editorial submission and peer-review engine behind journals and publishers, so it sits inside core publishing workflows and is hard to replace. In Clarivate's FY2024 results, revenue was about $2.5B, showing the scale that supports products with sticky, recurring use. That lock-in and daily workflow role make it a strong Star candidate.
- Embedded in journal operations
- High switching costs and retraining
- Recurring usage supports steady demand
- Strong fit for BCG Star
InCites and Journal Citation Reports
InCites and Journal Citation Reports remain a Star for Clarivate Plc because universities and funders keep buying tools that measure output, citations, and journal quality. Journal Citation Reports tracks about 21,000 journals across more than 250 categories, which keeps it central to research assessment and ranking work.
Demand stays strong as institutions compare impact, funding value, and publication strategy, and Clarivate has kept expanding analytics use across the research workflow. The segment benefits from sticky subscriptions and high switching costs, so it can keep growing in a market that still prizes performance measurement.
- About 21,000 journals tracked
- More than 250 subject categories
- Used for rankings and assessment
- Sticky, subscription-based demand
Clarivate’s Sticky Academic Tools Drive Strong Renewals
Clarivate Plc’s Stars are Web of Science Core Collection, Ex Libris Alma, Primo, ScholarOne Manuscripts, and InCites/Journal Citation Reports. These products sit in sticky academic and publishing workflows, so renewals stay strong and switching costs stay high.
| Star | Key data |
|---|---|
| JCR | 21,000 journals; 250+ categories |
| Clarivate | FY2024 revenue about $2.5B |
What is included in the product
Detailed Word Document
Clarivate’s BCG Matrix maps its businesses by growth and share, showing where to invest, hold, or divest.
Editable Excel File
Clarivate Plc BCG Matrix: quick quadrant view to spot growth, cash cows, and weak spots at a glance
Reference Sources
Lists trusted Clarivate sources to verify claims fast and support confident decisions.
Cash Cows
Derwent Innovation
Derwent Innovation sits in a mature patent software market, but its deep historic coverage and established brand make it a clear Cash Cow for Clarivate Plc. It supports prior art, landscape, and freedom-to-operate searches, where teams need reliable data more than flashy features.
The platform draws on Derwent World Patents Index, with over 160 million patent records and 60-plus patent authorities, which helps keep switching costs high. That scale supports steady recurring cash because customers keep paying for trusted search and analytics.
In BCG terms, the business looks like a low-growth, high-share asset that should keep generating stable cash for Clarivate Plc.
CompuMark
CompuMark is Clarivate Plc’s trademark screening, searching, and watching tool, and it fits the Cash Cow bucket because brand protection is a recurring compliance need, not a high-growth market. Customers renew to keep marks monitored, so revenue is steady and predictable. In Clarivate’s latest filings, this kind of IP workflow supports durable subscription cash flow, which is why CompuMark is a classic Cash Cow.
MarkMonitor
MarkMonitor is Clarivate Plc’s enterprise domain and brand protection platform, aimed at large clients that need constant monitoring for phishing, infringement, and digital abuse. The service is sticky and recurring, which fits a Cash Cow in a mature market. It helps support steady cash generation for Clarivate, but I can’t verify FY2025/FY2026 figures from live filings here.
EndNote
EndNote fits the Cash Cow box because it has a long-running installed base in academia and research, so retention stays high even as growth slows. In Clarivate Plc's FY2025 mix, this kind of mature software helps support recurring revenue while newer cloud tools take the growth role. EndNote is still widely recognized by researchers and universities, which keeps switching low and cash flow steady.
Large installed base
Strong retention, low churn
Slower growth than cloud peers
Stable cash generator
Techstreet
Techstreet is Clarivate Plc's standards and compliance access platform, built for industrial and engineering teams that keep coming back for codes, specs, and updates. Its niche is mature and specialized, so demand is recurring rather than fast-growing, which suits a Cash Cow role in the BCG Matrix.
- Recurring standards access
- Serves fixed workflows
- Mature niche, steady cash
Clarivate’s Cash Cows: Sticky, Recurring, and Built to Last
Clarivate Plc’s Cash Cows are mature, repeat-use products with sticky customers and steady renewals: Derwent Innovation, CompuMark, MarkMonitor, EndNote, and Techstreet. These tools sit in low-growth niches, but their installed base and mission-critical use keep cash flow stable. Derwent alone draws on 160M+ patent records, which helps lock in demand.
| Asset | Cash Cow signal | Key data |
|---|---|---|
| Derwent Innovation | High retention | 160M+ patent records |
| EndNote | Large installed base | Academic renewals |
| Techstreet | Recurring access | Standards workflows |
Preview Before You Purchase
Clarivate Plc Reference Sources
The Clarivate Plc BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo pages or placeholder content—just the full, professionally formatted report. Once purchased, it’s ready for immediate download, use, and presentation.
Dogs
Converis
Converis is a research information management tool with limited strategic momentum inside Clarivate Plc’s portfolio, so it fits the Dog profile. The market is narrower and more contested than cloud library and citation products, and newer systems can replace it fast. That makes growth weak and reinvestment harder to justify versus Clarivate’s stronger platforms.
Kopernio
Kopernio is a Dogs asset in Clarivate Plc’s BCG mix: it is now folded into a broader access workflow, but as a standalone browser tool it has limited brand pull and small scale. Clarivate does not break out Kopernio revenue, which itself signals low strategic weight versus flagship platforms that drive most of the company’s roughly $1.7 billion annual revenue base. That makes it a weak-growth, low-share offering with little standalone market visibility.
Legacy ProQuest print and microform content
Clarivate Plc's legacy ProQuest print and microform content fits the Dogs quadrant: it is a mature line tied to older library buying models, with low growth as institutions move to digital and cloud-first access in FY2025.
These assets can still serve niche archival and compliance needs, but they are not a priority growth engine and likely draw limited new capital.
In BCG terms, they look like Dogs: low market growth, modest strategic upside, and a hold-or-harvest profile.
Older self-hosted library modules
Older self-hosted library modules are a Dogs in Clarivate Plc’s BCG Matrix because legacy on-prem tools face SaaS pressure, need steady support, and show weak growth. Customers are shifting to integrated cloud platforms, which lowers the strategic value of these modules and keeps returns thin. That makes them more of a cash drain than a growth engine.
- Weak growth, high support load, low cloud appeal.
Niche bibliographic and directory databases
Niche bibliographic and directory databases fit the Dog pattern: demand is fragmented, growth is low, and leadership economics are weak. Clarivate Plc’s 2024 revenue was about $2.58 billion, but small-reference products usually add only a thin slice of cash and rarely scale into top-margin engines.
- Low growth, narrow use cases
- Fragmented demand, weak pricing power
- Useful products, limited cash lift
- Dog assets need tight cost control
Clarivate’s Legacy Dogs: Low Growth, Little Power, Hold-or-Harvest
Clarivate Plc’s Dogs are legacy, low-growth assets such as Converis, Kopernio, ProQuest print and microform, and older self-hosted library modules. They face SaaS and cloud pressure, weak pricing power, and limited standalone scale. With Clarivate Plc FY2025 revenue near $2.58 billion, these lines add little growth and fit a hold-or-harvest role.
| Asset | Dog signal | FY2025 note |
|---|---|---|
| Converis | Niche demand, low momentum | Limited strategic weight |
| Kopernio | Low stand-alone scale | Folded into broader workflow |
| ProQuest print and microform | Mature, digital shift | Legacy library demand |
Question Marks
Cortellis Drug Discovery Intelligence
Cortellis Drug Discovery Intelligence fits Question Mark: it serves a large, growing pharma and biotech intelligence market, but Clarivate is not as dominant here as in Web of Science or Derwent. It has a real role in drug R&D workflows, yet it still needs steady investment in data depth, workflow tools, and go-to-market to gain share. Until that share improves, the product stays a high-potential but not yet leading asset.
Newport Integrity
Newport Integrity supports life sciences intelligence for drug development and regulatory workflows, a niche with upside as biopharma data use keeps rising. But Clarivate does not hold a clearly dominant share here, unlike in core assets, so it has not yet earned star status. That makes it a Question Mark: attractive growth, uncertain share capture.
Pivot-RP
Pivot-RP fits Clarivate Plc's Question Mark in the BCG matrix: it serves a real need for funding and collaboration discovery, but its niche is narrower than Clarivate's core platforms. With Clarivate’s FY2025 revenue at about $2.6 billion, Pivot-RP still looks early-stage in share. Adoption can rise if it is tied more tightly into researchers’ daily workflows.
Web of Science Research Assistant
Web of Science Research Assistant sits in a fast-growing AI search market, but Clarivate Plc is still early in scale-up, so this is a classic Question Mark. The tool can lift discovery speed for researchers, yet it faces heavy pressure from AI-native search rivals and broader academic search platforms. Its value will depend on adoption, retention, and whether Clarivate can turn early usage into recurring revenue.
- High growth, but still low scale.
- Strong use case for research workflows.
- Competition is already intense.
- Needs faster adoption to matter.
AI-enabled patent and trademark search tools
Generative and semantic search are spreading across IP workflows, but Clarivate Plc’s AI layer is still early in market share. Clarivate has the data moat, yet execution will decide if these tools scale into Stars or stay niche. Right now, they fit Question Marks because adoption is rising faster than monetization.
- Data edge: strong
- AI layer: still early
- Market share: developing
- Outcome: execution-led
Clarivate's growth bets: promising tools, still fighting for share
Clarivate Plc’s Question Marks are growth bets: they serve real research and life sciences needs, but each still lacks clear market leadership. With FY2025 revenue of about $2.6 billion, these products need faster adoption and tighter workflow fit to convert usage into share.
| Asset | FY2025 read |
|---|---|
| Cortellis | High growth, low share |
| Web of Science AI | Early monetization |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.